Loading...
Loading...
CYCCP| Name | Value |
|---|---|
| Revenues | 16.0K |
| Cost of Revenue | 7.0K |
| Gross Profit | 9.0K |
| Operating Expense | 6,861.0K |
| Operating I/L | -6,845.0K |
| Other Income/Expense | 145.0K |
| Interest Income | 50.0K |
| Pretax | -6,699.0K |
| Income Tax Expense | -602.0K |
| Net Income/Loss | -6,097.0K |
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of medicines for cancer and proliferative diseases. Their product pipeline includes fadraciclib, a cyclin dependent kinase inhibitor in Phase 1/2 clinical trials for solid tumors and chronic lymphocytic leukemia, and CYC140, a polo-like kinase inhibitor in Phase 1/2 trials for advanced leukemias and solid tumors. Additionally, they are developing Sapacitabine, an oral prodrug for acute myeloid leukemia and myelodysplastic syndrome, and seliciclib, a CDK inhibitor in Phase 2 trials for Cushing's disease and rheumatoid arthritis.
